TOKYO–(BUSINESS WIRE)–Malignant Tumor Treatment Technologies, Inc. (Headquarters: Tokyo; President and CEO: Toshiyasu Miyazaki; “MT3”) today announced that the Japanese drug regulatory agency, the Ministry of Agriculture, Forestry and Fisheries, has approved LAVURCHIN® as a Radiosensitizer for the treatment of dogs with stage III or IV nasal tumors.
Radiation therapy is an important treatment for malignant tumors that cannot be completely removed by surgery, and has made significant progress in both the human and veterinary fields in recent years. However, challenges such as limitations in the number of radiotherapy sessions and decreased efficacy as tumors progress highlight the need for radiosensitizers to enhance treatment efficacy. Although several candidate substances are being studied, none has received drug approval due to concerns about side effects.
After two and a half decades of long and challenging efforts, “LAVURCHIN®” has emerged as a breakthrough solution, becoming the world’s first radiation sensitizer in the veterinary field approved by Japan’s Ministry of Agriculture, Forestry and Fisheries (MAFF) , the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Derived from marine organisms, including sea urchins and deep-sea seaweed from Hokkaido, Japan’s northern region, this innovative formulation not only enhances the effects of radiotherapy, but also minimizes damage to normal tissue, ensuring high safety standards.
“We are pleased to announce the approval of LAVURCHIN® as the world’s first radiosensitizer for dogs,” said Toshiyasu Miyazaki, President and CEO of MT3. “This important milestone demonstrates our commitment to advancing cancer treatments. and improving the lives of animals and humans. We will continue our efforts to provide LAVURCHIN® to people in need around the world.”
While being approved in Japan, MT3 is conducting clinical research on “LAVURCHIN®” in the United States, demonstrating a global perspective. The company hopes to bring this revolutionary product to global markets, including the United States, Europe and Asia. Additionally, future expansion into human medicine is also being considered.
Contact information
For more information, please contact:
Malignant Cancer Therapeutics Technologies Inc. (MT3)
Animal Health Division
Tel: +81-3-6809-6367
Email: info@mt3.co.jp
Business hours: Monday to Friday, 10:00am to 5:00pm (JST)
Source link
Content provided by Business Wire. Toutiao is not responsible for the content provided or any links related to that content. Toutiao is not responsible for the accuracy, topicality or quality of the content.
